A fund manager has named the CSL Ltd (ASX: CSL) share price within an ASX hall of fame.
CSL shares are currently swapping hands at $266.05, a 0.55% fall. In comparison, the S&P/ASX 200 Index (ASX: XJO) is up 0.11% today.
So why has this biotechnology giant received this accolade?
Why is CSL an ASX hall of famer?
QVG Capital has listed multiple shares in a list of ‘ASX Hall of Famers’ and CSL is one of them. Shares that made the cut are seen as some of the greatest ASX-listed companies of all time.
REA Group Limited (ASX: REA), Objective Corporation Limited (ASX: OCL), Aristocrat Leisure Limited (ASX: ALL), Reece Ltd (ASX: REH), Cochlear Limited (ASX: COH), Domino’s Pizza Enterprises Ltd (ASX: DMP), ARB Corporation Limited (ASX: ARB), Resmed CDI (ASX: RMD), and JB Hi-Fi Limited (ASX: JBH) are also named.
Commenting on this hall of fame listing on Livewire, QVG portfolio manager Chris Prunty said:
All these companies have been at least 20-baggers with CSL and REA returning over 100x to patient shareholders.
What’s clear from the data is that high returns on capital and compounding revenue growth for many years in the teens is the ‘secret’ to gaining access to this elite cohort.
The team at QVG listed three common characteristics of the shares that made the list. High returns on capital combined with revenue growth, margins that demonstrate pricing power or unit economics that crush the competition, and strong balance sheets.
CSL reported revenue growth of 4% in its latest half-yearly results and a net profit after tax of $1.76 billion. The EBIT margin, a measure of the profitability of the company taking into account interest and taxes, was 41.1%. The company is predicting a net profit after tax of between $2.15 billion and $2.25 billion in FY22. The company declared an interim dividend of $1.46 per share, up 8%. The CSL share price jumped more than 8% on the back of these results.
Citi has recently maintained a buy rating and placed a $335 price target on CSL shares.
CSL has been operating for more than a century and listed on the ASX in 1994.
CSL share price snapshot
The CSL share price has shed nearly 9% so far this year, while it is down 0.1% year to date.
For perspective, the benchmark S&P/ASX 200 Index (ASX: XJO) has gained 9% in the past 12 months.
CSL has a market capitalisation of about $128 billion based on its current share price.
The post Do CSL shares deserve a spot in the ASX ‘hall of fame’? appeared first on The Motley Fool Australia.
Should you invest $1,000 in CSL right now?
Before you consider CSL , you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and CSL wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of January 13th 2022
More reading
- Top brokers name 3 ASX shares to buy today
- The next ASX share ready to join the 20-bagger club: expert
- Which ASX 200 shares is AFIC (ASX:AFI) betting on to make money?
- The company outperformed when it last reported, so why has the CSL share price been languishing?
- 3 buy-rated blue chip ASX 200 shares according to experts
The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/ZYfu3G0
Leave a Reply